Robert Laningham, MD
Family Medicine · Conroe, TXNPI 1700973682
Payments from drug & device makers
Across 221 payments — averaging $4477.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$548K
- Pfizer$434K
- Evofem Biosciences, Inc.$5K
- AbbVie$518
- Dexcom, Inc.$517
- Amgen$294
- plus $2K from 26 others
Across 9 payments — averaging $83,560 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$752K
What the payments were for
- Food & beverage$2,92899%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 7 | $548,071 |
| Pfizer | 42 | $433,524 |
| Evofem Biosciences, Inc. | 1 | $5,000 |
| AbbVie(2 entities) | 38 | $518 |
| Dexcom, Inc. | 25 | $517 |
| Amgen | 25 | $294 |
| Abbott | 9 | $207 |
| Astellas Pharma US Inc | 7 | $175 |
| Novo Nordisk | 8 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $120 |
| GSK | 7 | $106 |
| Inspire Medical Systems, Inc. | 4 | $102 |
| AstraZeneca | 7 | $96 |
| Johnson & Johnson | 6 | $85 |
| Lilly USA, LLC | 5 | $81 |
| Stemline Therapeutics Inc. | 2 | $71 |
| Indivior Inc. | 2 | $56 |
| Medtronic | 3 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Coloplast | 1 | $39 |
| Medline Industries LP | 1 | $22 |
| Corcept Therapeutics | 1 | $21 |
| Orexo US, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Corium, LLC | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
| Echosens North America, Inc. | 1 | $11 |
How this compares
$989,470 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $97,116 |
| TrulicityDulaglutide | 70 | $72,761 |
| EliquisApixaban | 51 | $67,956 |
| JardianceEmpagliflozin | 37 | $43,020 |
| XareltoRivaroxaban | 28 | $37,305 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $34,465 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 234 | $34,182 |
| EntrestoSacubitril/Valsartan | 27 | $25,683 |
| MounjaroTirzepatide | 15 | $18,244 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 27 | $17,149 |
| JanuviaSitagliptin Phosphate | 12 | $16,352 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $14,848 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $11,851 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $10,465 |
| Liothyronine Sodium | 232 | $9,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $134 | $97,11685 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $81 | $91,00585 claims |
| PfizerEliquis | $433,524 | $67,95651 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $106 | $55,23596 claims |
| Boehringer IngelheimJardiance | $16 | $43,02037 claims |
| Johnson & JohnsonXarelto | $85 | $37,30528 claims |
| MerckJanuvia, Janumet | $14 | $24,34523 claims |
| Indivior Inc.Suboxone | $56 | $17,14927 claims |
| Astellas Pharma US IncMyrbetriq | $175 | $9,20814 claims |
| AstraZenecaSymbicort | $96 | $5,84114 claims |
| Sanofi-aventis U.S. LLCLantus | $41 | $3,13615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Conroe
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.